Search

Ian E Krop

age ~59

from New Haven, CT

Get Report
Also known as:
  • Ian J Krop
  • Inian E Corp
Related to:
Connected to:

Ian Krop Phones & Addresses

  • New Haven, CT
  • Madison, CT
  • 9 Braddock Park, Boston, MA 02116 • (617)2664342
  • Scituate, MA
  • Newton Lower Falls, MA
  • Baltimore, MD
  • Washington, DC

Work

  • Company:
    Brigham and Women's Hospital
  • Address:
    75 Francis Street, Boston, MA 02115

Education

  • School / High School:
    Johns Hopkins University School Of Medicine
    1996

Languages

English

Awards

Healthgrades Honor Roll

Ranks

  • Certificate:
    Internal Medicine, 1999

Specialities

Oncology • Medical Oncology

Medicine Doctors

Ian Krop Photo 1

Dr. Ian E Krop, Framingham MA - MD (Doctor of Medicine)

view source
Specialties:
Oncology
Medical Oncology
Address:
761 Worcester Rd, Framingham, MA 01701
(508)7881700 (Phone)
Certifications:
Internal Medicine, 1999
Medical Oncology, 2002
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
761 Worcester Rd, Framingham, MA 01701

Brigham and Women's Hospital
75 Francis Street, Boston, MA 02115

Massachusetts General Hospital
55 Fruit Street, Boston, MA 02114

North Shore Medical Center - Salem Hospital
81 Highland Avenue, Salem, MA 01970
Education:
Medical School
Johns Hopkins University School Of Medicine
Graduated: 1996
Medical School
Johns Hopkins Hospital
Graduated: 1996
Medical School
Dana Farber Cancer Institute
Graduated: 1996
Ian Krop Photo 2

Ian E. Krop

view source
Specialties:
Medical Oncology
Work:
Dana-Farber Cancer Institute Center For Neurology-Oncology
450 Brookline Ave FL 10, Boston, MA 02215
(617)6326633 (phone), (617)6324773 (fax)
Education:
Medical School
Johns Hopkins University School of Medicine
Graduated: 1996
Conditions:
Malignant Neoplasm of Female Breast
Multiple Myeloma
Ovarian Cancer
Languages:
Chinese
English
French
Spanish
Description:
Dr. Krop graduated from the Johns Hopkins University School of Medicine in 1996. He works in Boston, MA and specializes in Medical Oncology. Dr. Krop is affiliated with Boston Childrens Hospital, Brigham & Womens Hospital and MassGeneral For Children At North Shore Medical Center.
Ian Krop Photo 3

Ian Elliott Krop, Boston MA

view source
Specialties:
Internal Medicine
Hematology & Oncology
Medical Oncology
Work:
Dana-Farber Cancer Institute
44 Binney St, Boston, MA 02115
Dana-Farber Cancer Institute
450 Brookline Ave, Boston, MA 02215
Education:
Johns Hopkins University (1996)
Ian Krop Photo 4

Ian Elliott Krop, Boston MA

view source
Specialties:
Oncologist
Address:
44 Binney St, Boston, MA 02115
Education:
Doctor of Medicine
Name / Title
Company / Classification
Phones & Addresses
Ian Elliott Krop
Krop, Dr. Ian E
Internist
44 Binney St, Boston, MA 02115
(617)6323000

Us Patents

  • Hin-1, A Tumor Suppressor Gene

    view source
  • US Patent:
    7625715, Dec 1, 2009
  • Filed:
    Nov 5, 2004
  • Appl. No.:
    10/982142
  • Inventors:
    Kornelia Polyak - Brookline MA, US
    Dennis Sgroi - Winchester MA, US
    Ian Krop - Boston MA, US
    Dale Porter - Boston MA, US
  • Assignee:
    Dana-Farber Cancer Institute, Inc. - Boston MA
  • International Classification:
    G01N 33/574
    G01N 33/53
    C12Q 1/68
  • US Classification:
    435 723, 435 6, 435 71
  • Abstract:
    The invention encompasses isolated DNAs encoding HIN-1 polypeptides, vectors containing such DNAs, cells containing the vectors, and isolated HIN-1 polypeptides. The invention also features methods of making and using HIN-1 polypeptides.

  • Hin-1, A Tumor Suppressor Gene

    view source
  • US Patent:
    8034561, Oct 11, 2011
  • Filed:
    Nov 30, 2009
  • Appl. No.:
    12/627939
  • Inventors:
    Kornelia Polyak - Brookline MA, US
    Dennis Sgroi - Winchester MA, US
    Ian Krop - Boston MA, US
    Dale Porter - Boston MA, US
  • Assignee:
    Dana-Farber Cancer Institute, Inc. - Boston MA
    The General Hospital Corporation - Boston MA
  • International Classification:
    C12Q 1/68
    C07H 21/04
  • US Classification:
    435 6, 536 235
  • Abstract:
    The invention encompasses isolated DNAs encoding HIN-1 polypeptides, vectors containing such DNAs, cells containing the vectors, and isolated HIN-1 polypeptides. The invention also features methods of making and using HIN-1 polypeptides.

  • Hin-1, A Tumor Suppressor Gene

    view source
  • US Patent:
    20020183501, Dec 5, 2002
  • Filed:
    Feb 22, 2002
  • Appl. No.:
    10/081817
  • Inventors:
    Kornelia Polyak - Brookline MA, US
    Dennis Sgroi - Winchester MA, US
    Ian Krop - Boston MA, US
    Dale Porter - Boston MA, US
  • International Classification:
    C07H021/02
    C07H021/04
    C07K001/00
    C07K014/00
    C07K017/00
  • US Classification:
    536/023100, 530/350000
  • Abstract:
    The invention encompasses isolated DNAs encoding HIN-1 polypeptides, vectors containing such DNAs, cells containing the vectors, and isolated HIN-1 polypeptides. The invention also features methods of making and using HIN-1 polypeptides.

Facebook

Ian Krop Photo 5

Tsuma Ian Krop

view source
Friends:
Samuel Mbugua, Charlie Shin' Mwangi

News

Preliminary Studies Target Advanced Breast Cancers

Preliminary Studies Target Advanced Breast Cancers

view source
  • Study lead author Dr. Ian Krop, director of clinical research with the Breast Oncology Center at Dana-Farber Cancer Institute in Boston, said about 70 percent of women with breast cancer have this type of cancer, in which the hormone estrogen boosts cancer growth. The women were also HER2-negative, SOURCES: Ian Krop, M.D., Ph.D., director, clinical research, Breast Oncology Center, Dana-Farber Cancer Institute, Boston, Mass.; Debu Tripathy, M.D., professor and chair, Breast Medical Oncology, MD Anderson Cancer Center, Houston, Texas; 2014 San Antonio Breast Cancer Symposium, Dec. 9-13, 2014
  • Date: Dec 10, 2014
  • Category: Health
  • Source: Google
Breast Cancer Medications Show Promise In Second Trial

Breast Cancer Medications Show Promise In Second Trial

view source
  • The two medications being tested will treat cancer that is estrogen-receptor-positive, according to HealthDay News. The study's lead author, Dr. Ian Krop, said that about 70 percent of women with breast cancer have this type of cancer.
  • Date: Dec 10, 2014
  • Category: Health
  • Source: Google

Novel Breast CA Drugs Show Promise in Early Trials

view source
  • For one study, Ian Krop, MD, PhD, director of clinical research with the Breast Oncology Center at the Dana-Farber Cancer Institute in Boston, and colleagues randomly assigned postmenopausal women with metastatic cancer to fulvestrant with a placebo (79 patients) or fulvestrant with the experimental
  • Date: Dec 10, 2014
  • Source: Google

Youtube

Dr. Ian Krop on HER2 Breast Cancer | Dana-Far...

Dr. Ian Krop on HER2 Breast Cancer | Dana-Farber C...

Dr. Ian Krop, of the Breast Cancer Treatment Center at Dana-Farber, ta...

  • Duration:
    1m 9s

Developing drugs to target breast cancer: Dr....

Developing drugs to target breast cancer: Dr. Ian ...

Dr. Ian Krop, a medical oncologist in Dana-Farber's Breast Cancer Trea...

  • Duration:
    2m 27s

Dr. Ian Krop, MD, PhD - Yale Cancer Center, USA

Dr. Ian Krop, MD, PhD - Yale Cancer Center, USA

Trastuzumab deruxtecan vs physician's choice in patients with HER2+ un...

  • Duration:
    4m 50s

The meaning of residual disease in breast can...

The meaning of residual disease in breast cancer

Ian Krop, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, shares in...

  • Duration:
    5m 47s

Ian Krop, MD, PhD - Dana-Farber Cancer Instit...

Ian Krop, MD, PhD - Dana-Farber Cancer Institute

Dr. Ian Krop's presentation on new approaches to metastatic breast can...

  • Duration:
    21m 24s

Dr. Krop on the Impact of Recent Advances in ...

Dr. Krop on the Impact of Recent Advances in Breas...

Ian E. Krop, MD, PhD, chief, Breast Oncology, Susan F. Smith Center fo...

  • Duration:
    1m 53s

Googleplus

Ian Krop Photo 6

Ian Krop

Get Report for Ian E Krop from New Haven, CT, age ~59
Control profile